Article in Cancers, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
7 authors.
Renáta GubánDepartment of Dermato-Oncology, National Institute of Oncology and National Tumor Laboratory, 1122 Budapest, Hungary.ORCID 0009-0004-9126-5510
Petra ParragNational Cancer Registry, National Institute of Oncology and National Tumor Laboratory, 1122 Budapest, Hungary.
Mihály Tamás KispálDepartment of Dermato-Oncology, National Institute of Oncology and National Tumor Laboratory, 1122 Budapest, Hungary.
Kata CzirbeszDepartment of Dermato-Oncology, National Institute of Oncology and National Tumor Laboratory, 1122 Budapest, Hungary.
Tímea DanyiDepartment of Dermato-Oncology, National Institute of Oncology and National Tumor Laboratory, 1122 Budapest, Hungary.
István KenesseyNational Cancer Registry, National Institute of Oncology and National Tumor Laboratory, 1122 Budapest, Hungary.ORCID 0000-0002-6963-8489
Gabriella LiszkayDepartment of Dermato-Oncology, National Institute of Oncology and National Tumor Laboratory, 1122 Budapest, Hungary.
Funding
National Research, Development and Innovation Fund of the Ministry of Culture and Innovation under the Hungarian Thematic Excellence Program TKP2021-EGA-44National Research, Development and Innovation Office and Tasks Related to the National Health Strategy IV/651/2022/EKFthe National Research, Development and Innovation Fund of the Ministry of Culture and Innova-tion under the National Laboratories Program National Tumor Biology Laboratory (2022-2.1.1-NL-2022-00010)
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Characterization of Melanoma in Hungary Based on a Retrospective Single-Center Study Between 2001 and 2018. · full record | OpenQuestion